Vaping Linked to Cancer Risk

Australian researchers have reported that vaping is strongly linked to early biological warning signs associated with higher risks of lung and oral cancer, citing evidence of DNA damage and inflammation in the body. The assessment was published on Tuesday in the journal Carcinogenesis and was led by the University of New South Wales (UNSW) in Sydney.

The review examined findings drawn from animal studies, human case reports, and laboratory research conducted between 2017 and 2025. Based on that body of evidence, the authors concluded that e-cigarettes are likely to trigger pre-carcinogenic changes in cells and tissues in the oral cavity, mouth, and lungs. The paper describes these changes as biological alterations that are known to occur before cancer develops.

The researchers also highlighted a key limitation: long-term human data directly tracking cancer development from vaping remains limited. They attributed this gap to the relatively recent arrival of modern e-cigarettes, which means large, long-duration datasets are not yet widely available. Even so, the review argues that the observed patterns of DNA damage and inflammation align with mechanisms that can precede cancer, and therefore warrant attention from public health authorities.

Co-author Adjunct Professor Bernard Stewart said the study’s focus was not to estimate how many people might ultimately develop cancer. Instead, he emphasized that the central question was whether vaping causes the kinds of biological changes that can set the stage for cancer. The authors framed their conclusions as an assessment of early indicators rather than a definitive count of future cancer cases.

In their call to action, the researchers urged regulators to respond to what they described as emerging evidence, particularly to protect young people. They argued that policy should not depend on waiting decades for long-term, definitive human outcomes when early warning signals are already being documented across multiple research approaches.

The paper positions this as a public health decision point, balancing the current limits of long-horizon data against the presence of biological markers associated with cancer risk.

For global markets and politics, the findings add to ongoing regulatory debates over e-cigarettes and nicotine products, with potential relevance for consumer health policy and compliance requirements across jurisdictions. The authors’ emphasis on early biological changes, alongside acknowledged uncertainty about long-term cancer incidence, underscores that the evidence base is still developing even as pressure grows for regulatory responses.